Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nepafenac vs Patching for Pain Control After Intravitreal Injection
NCT03918590Phase 4Unknown
- Sponsor
- New York Eye and Ear Infirmary of Mount Sinai
- Start
- Dec 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of nepafenac (3 arms), sponsored by New York Eye and Ear Infirmary of Mount Sinai. Primary endpoint: Post Intravitreal Injection Measurement of Pain at 24 hours. Status: unknown.
02
Drugs
nepafenac
Beyond the preview
Go deeper on NCT03918590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03918590.